ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Prostate Cancer

Howard I. Scher, MD

Howard I. Scher, MD, on the Prostate Cancer Working Group 3 Consensus

Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in castration-resistant prostate cancer (Abstract 5000).

Leukemia

Lymphoma

Asher Alban Chanan-Khan, MD

Asher Chanan-Khan, MD, Summarizes Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

Asher Alban Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discusses an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).

Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic colorectal cancer (Abstracts 103 and 3511).

Skin Cancer

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD, on The DECOG Trial on Sentinel Lymph Node–Positive Melanoma

Claus Garbe, MD, of the University of Tuebingen, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss the survival of sentinel lymph node-positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).

Oct

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

Howard I. Scher, MD, on the Prostate Cancer Working Group 3 Consensus

Asher Chanan-Khan, MD, Summarizes Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD, on The DECOG Trial on Sentinel Lymph Node–Positive Melanoma

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer

Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology

FDA Approves First-Line Pirtobrutinib for CLL-SLL